Direkt zum Inhalt
Merck

Fortfahren mit

1478800

USP

Orlistat

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

(−)-Tetrahydrolipstatin, N-Formyl-L-leucin-(1S)-1-{[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]-methyl}-dodecylester, Ro-18-0647

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis
200 mg
Warenkorb auf Verfügbarkeit prüfen
€ 903,00

Über diesen Artikel

Empirische Formel (Hill-System):
C29H53NO5
CAS-Nummer:
Molekulargewicht:
495.73
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:

€ 903,00


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


grade

pharmaceutical primary standard

API family

orlistat

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O

InChI

1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1

InChI key

AHLBNYSZXLDEJQ-FWEHEUNISA-N

Gene Information

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem/physiol Actions

Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.
Solution is not completely clear, small particles may remain floating.

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
PHR1445O41391478811
Orlistat United States Pharmacopeia (USP) Reference Standard

USP

1478800

Orlistat

manufacturer/tradename

USP

manufacturer/tradename

-

manufacturer/tradename

-

manufacturer/tradename

USP

grade

pharmaceutical primary standard

grade

certified reference material, pharmaceutical secondary standard

grade

-

grade

pharmaceutical primary standard

format

neat

format

neat

format

-

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

-

application(s)

pharmaceutical (small molecule)

API family

orlistat

API family

orlistat

API family

-

API family

orlistat

Gene Information

human ... LIPF(8513), PNLIP(5406)

Gene Information

human ... LIPF(8513), PNLIP(5406)

Gene Information

human ... LIPF(8513), PNLIP(5406)

Gene Information

-


Still not finding the right product?

Explore all of our products under Orlistat


Lagerklasse

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



Theodosios D Filippatos et al.
Drug safety, 31(1), 53-65 (2007-12-22)
Orlistat, an anti-obesity drug, is a potent and specific inhibitor of intestinal lipases. In light of the recent US FDA approval of the over-the-counter sale of orlistat (60 mg three times daily), clinicians need to be aware that its use
[Pharmacological sheet. Orlistat, oral administration (Xenical, Alli). ].
Journal de pharmacie de Belgique, (2)(2), 67-68 (2009-09-11)
E García Díaz et al.
Nutricion hospitalaria, 26(3), 451-457 (2011-09-06)
The prevalence of obesity, a serious public health problem, is increasing among teenagers and thus also increases cardiovascular morbidity and mortality in adulthood. To provide a systematic review of the best evidence about the effect of sibutramine and orlistat in



Global Trade Item Number

SKUGTIN
1478800-200MG04061838737694

Questions

Reviews

No rating value

Active Filters